Jack Aiello

Diagnosed with myeloma in 1995, Jack is strong proponent of patients participating in clinical trials so that, in the future, myeloma and other cancers will be known as curable diseases. He is a proud facilitator of the San Francisco Bay Area Myeloma Support Group.

Follow Jack on Twitter
Jack Aiello

Summary of ASH 2018

Jack Aiello |

December 4, 2018 Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early this morning focused on a phase III trial using Darzalex (daratumumab) in front-line therapy plus Rev-dex versus Rev-dex only for transplant-ineligible patients. The abstract # LBA-2 showed that the addition of Dara decreased the […]

Day 3 – Saving the Best for Last

Jack Aiello |

December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]

Day 2: A Busy Day at ASH

Jack Aiello |

Day 2: A busy day at ASH December 2, 2018 Today I attended oral presentations from 8 a.m. to 6 p.m. with a few short breaks to check out posters and exhibits as well as meet with Pharma companies. Let me discuss several findings from several oral presentations (#abstract). Maintenance Therapy with Ninlaro (Ixazomib)….Tourmaline 3 […]

Day 1: Dr Anderson Led an Outstanding Education Session

Jack Aiello |

Day 1: First full day of ASH Saturday December 1, 2018 It’s nearly 10 p.m. as I begin to write my daily blog, but I’m still wide awake & enthusiastic, having just attended the IMF’s annual Brian D. Novis Research Grant Awards reception. After listening to some wonderful patient stories, I was encouraged to see six young […]

Day 0 – Symposium Day at ASH2018

Jack Aiello |

Friday, November 30, 2018 November 30th is actually the day before ASH officially begins, often called “Symposium” day. However, my first session was last night’s Bone Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup MRD and Immune Profiling Meeting, a group focused supporting myeloma clinical trials involving transplants and immunotherapies. There were probably 100 […]

How Do Patients Learn at ASH?

Jack Aiello |

Soon I’ll be off to San Diego, the site of this year’s American Society of Hematology (ASH) conference. ASH is all about blood cancers (leukemia, lymphoma, multiple myeloma), and there are nearly 700 oral presentations and posters on myeloma alone. I’m so grateful to the International Myeloma Foundation (IMF) and their sponsors for sending me, […]